Skip to content

Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509412-28-00
Acronym
NN9490-7678
Enrollment
339
Registered
2024-07-11
Start date
2024-07-26
Completion date
2025-10-08
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Change in HbA1c

Detailed description

Relative change in body weight, Change in body weight, Change in fasting plasma glucose (FPG), CGM: Change in time in range (TIR) 3.9–10.0 mmol/L (70–180 mg/dL), Change in body mass index (BMI), Change in waist circumference, Change in systolic blood pressure (SBP), Change in average 24 hour systolic blood pressure (SBP), Change in high sensitivity C-Reactive Protein (hsCRP), Change in total cholesterol, Change in high-density lipoprotein (HDL) cholesterol, Change in low-density lipoprotein (LDL) cholesterol, Change in triglycerides, Number of adverse events, Change in Urinary Albumin/Creatinine Ratio (UACR), Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g), Change in eGFR creatinine-cystatin C based CKD-EPI

Interventions

DRUGPlacebo C tablets
DRUGMETFORMIN
DRUGDAPAGLIFLOZIN

Sponsors

Novo Nordisk A/S
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in HbA1c

Secondary

MeasureTime frame
Relative change in body weight, Change in body weight, Change in fasting plasma glucose (FPG), CGM: Change in time in range (TIR) 3.9–10.0 mmol/L (70–180 mg/dL), Change in body mass index (BMI), Change in waist circumference, Change in systolic blood pressure (SBP), Change in average 24 hour systolic blood pressure (SBP), Change in high sensitivity C-Reactive Protein (hsCRP), Change in total cholesterol, Change in high-density lipoprotein (HDL) cholesterol, Change in low-density lipoprotein (LDL) cholesterol, Change in triglycerides, Number of adverse events, Change in Urinary Albumin/Creatinine Ratio (UACR), Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g), Change in eGFR creatinine-cystatin C based CKD-EPI

Countries

Bulgaria, Croatia, Germany, Greece, Hungary, Poland, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026